Girolline, an antitumor compound isolated from a sponge, induces G2/M cell cycle arrest and accumulation of polyubiquitinated p53

Biological and Pharmaceutical Bulletin

Volumn 27, Issue 5, 2004, Pages 699-701

  Tsukamoto, Sachiko ^a   Yamashita, Katsumi ^a   Tane, Kazuhiro ^a   Kizu, Ryoichi ^a   Ohta, Tomihisa ^a   Matsunaga, Shigeki ^b   Fusetani, Nobuhiro ^b   Kawahara, Hiroyuki ^c   Yokosawa, Hideyoshi ^c  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Cell cycle; Girolline; p53; Proteasome; Ubiquitin

Indexed keywords

ANTINEOPLASTIC AGENT; CELL PROTEIN; GIROLLINE; LEPTOMYCIN B; PROTEASOME; PROTEIN P53; POLYUBIQUITIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DRUG EFFECT; DRUG ISOLATION; DRUG MECHANISM; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; IN VITRO STUDY; METAPHASE; NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN TRANSPORT; SPONGE (PORIFERA); TUMOR CELL LINE; UBIQUITINATION; ANIMAL; AXINELLA; CELL DIVISION; COMPARATIVE STUDY; DRUG ANTAGONISM; ISOLATION AND PURIFICATION; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; AXINELLA; CELL DIVISION; G2 PHASE; HELA CELLS; HUMANS; POLYUBIQUITIN; PROTEIN TRANSPORT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 9644254378     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.27.699     Document Type: Article

References (17)

1. Hershko A., Ciechanover A., Annu. Rev. Biochem., 67, 425-479 (1998).
2. Voges D., Zwickl P., Baumeister W., Annu. Rev. Biochem., 68, 1015-1068 (1999).
3. Pickart C. M., Annu. Rev. Biochem., 70, 503-533 (2001).
4. Glickman M. H., Ciechanover A., Physiol. Rev., 82, 373-428 (2002).
5. Alarcon-Vargas D., Ronai Z., Carcinogenesis, 23, 541-547 (2002).
6. Oren M., Cell Death Differ., 10, 431-442 (2003).
7. Ahond A., Bedoya-Zurita M., Colin M., Fizames C., Laboute P., Lavelle F., Laurent D., Poupat C., Pusset J., Pusset M., Thoison O., Potier P., C. R. Acad. Sci. Paris 2, 307, 145-148 (1988).
8. Lavelle F., Zerial A., Fizames C., Rabault B., Curaudeau A., Invest. New Drugs, 9, 233-244 (1991).
9. Colson G., Rabault B., Lavelle F., Zerial A., Biochem. Pharmacol., 43, 1717-1723 (1992).
10. Catimel G., Coquard R., Guastalla J. P., Merrouche Y., Le Bail N., Klink Alakl M., Dumortier A., Foy M., Clavel M., Cancer Chemother. Pharmacol., 35, 246-248 (1995).
11. Tsukamoto S., Tane K., Ohta T., Matsunaga S., Fusetani N., van Soest R. W. M., J. Nat. Prod., 64, 1576-1578 (2001).
12. Fujimuro M., Sawada H., Yokosawa H., FEBS Lett., 349, 173-180 (1994).
13. Taylor W. R., Stark G. R., Oncogene, 20, 1803-1815 (2001).
14. Nakayama K., Nagahama H., Minamishima Y. A., Matsumoto M., Nakamichi I., Kitagawa K., Shirane M., Tsunematsu R., Tsukiyama T., Ishida N., Kitagawa M., Nakayama K., Hatakeyama S., EMBO J., 19, 2069-2081 (2000).
15. Hara T., Kamura T., Nakayama K., Oshikawa K., Hatakeyama S., Nakayama K., J. Biol. Chem., 276, 48937-48943 (2001).
16. Freedman D. A., Levine A. J., Mol. Cell. Biol., 18, 7288-7293 (1998).
17. Hartmann-Petersen R., Seeger M., Gordon C., Trends Biochem. Sci., 28, 26-31 (2003).